A Question That Could Change Lives – An analysis of the Swiss Federal Council’s regulatory course and its practical implications for patient care and innovation. 

Switzerland stands at a turning point in healthcare. The central question is: When will Swiss patients be able to benefit from medical devices that are already approved in the USA – but not (yet) available in Europe? 

For years, experts have watched with concern as Switzerland has increasingly disconnected from innovative technologies due to the absence of an agreement with the EU (MRA). Heart implants, robot-assisted surgical systems, digital diagnostics – many of these devices are first used in the USA. This is due in part to FDA approval, which is often quicker and more innovation-friendly than the European CE procedure. 

With the Federal Council’s decision of April 30, 2025, a regulatory course correction has been initiated: Switzerland wants to approve FDA-authorized products in the future – through an independent process. But how quickly can such a system shift be implemented? And when will it be noticeable for patients? 

A Historic Decision With Far-Reaching Implications 

Motion 20.3211, the basis for the Federal Council’s action, was submitted as early as 2020 – in response to the uncertainties following the expiration of the MRA in the field of medical technology. Its implementation amounts to nothing less than the establishment of an independent market access pathway for medical devices approved by the U.S. FDA. 

This is new: until now, Switzerland strictly followed EU certification. The new approach would create an alternative approval route – initially for specific risk classes, and potentially broader later. 

The decision is highly significant: it promises better access to innovative products and regulatory sovereignty. At the same time, it demands a systemic transformation – legally, technically, and organizationally. 

The Planned System: Recognition With Conditions 

At the heart of the new model is the concept of ‘Regulatory Reliance’. FDA approval is not simply accepted automatically but reviewed through a structured short procedure. In the future, not only government bodies but also private conformity assessment bodies (CABs), accredited by Swissmedic, will be responsible. 

These CABs are to check FDA dossiers for compliance with Swiss standards – for example in product safety, post-market surveillance, or technical documentation. 

Swissmedic will remain the supervisory authority, responsible for monitoring CABs, market controls, and handling incidents. The system is thus a hybrid of state control and private implementation. 

The Timeline: From Draft to Availability 

The path to practical application is long. After publishing the guidelines, a draft regulation must now be prepared. This is expected to be submitted for public consultation (Vernehmlassung) by the end of 2025 – allowing associations, experts, and cantons to provide input. 

Depending on the feedback received, the draft may need revision before the Federal Council can adopt it. The earliest the regulation could come into force is late summer or fall 2026. 

Yet even with a valid regulation, access to FDA products will not be immediate. CABs must first be accredited by the Swiss Accreditation Service (SAS) – a process that may take another nine to twelve months. Only then can manufacturers submit their products for review. 

Realistically compiling all stages leads to this picture: initial practical availability of FDA-approved medical devices for patients is not expected before the first half of 2028. 

Why 2028 Is Realistic 

This forecast is based not only on legislative experience in Switzerland but also on international projects. In the UK, implementing a comparable system (MHRA’s ‘International Recognition’) took around 18 months. 

Additionally, Switzerland’s regulatory system is known for its thoroughness. Every step – from legal drafting to CAB accreditation and reimbursement integration – requires time and resources. 

Swissmedic faces a major challenge: coordinating a new approval model while continuing its existing tasks, such as MDR market monitoring. Clinics, hospitals, and insurers must also align their processes with the new products. 

Political Context: Opportunities and Risks 

The opening to FDA products doesn’t occur in a vacuum. Switzerland is simultaneously negotiating a new bilateral agreement with the EU. Critics fear that this solo effort in the medical field could strain relations with Brussels – especially if FDA alternatives displace CE-marked products. 

The Federal Council has emphasized that the new procedure is not meant to replace EU approval, but to complement it – as a pragmatic response to supply gaps. Whether the EU will accept this rationale remains to be seen. Political resistance from Brussels cannot be ruled out, but currently seems unlikely. 

Industry Must Step Up 

While political negotiations continue, the responsibility now lies with industry. Those seeking to bring FDA products to Switzerland must prepare early: dossiers must comply with both FDA and Swissmedic standards, labeling must be adapted, and post-market data must be ready. 

Early dialogue with future CABs should begin now. Only those involved from the start will be among the first manufacturers to have their products approved under the new system – and gain access to the Swiss market. 

Payers and HTA committees must also prepare to evaluate new technologies more rapidly and integrate them into reimbursement schemes. Without financial viability, regulatory access alone won’t suffice. 

What’s at Stake 

The significance of this regulatory step can hardly be overstated. It’s not just a technical issue – it’s about innovation access, patient safety, and Switzerland’s international competitiveness in healthcare. 

Supply shortages experienced in recent years with heart implants or in-vitro diagnostics could be avoided with FDA access. At the same time, Switzerland would become more independent from the often overburdened EU approval structure. 

However, all of this hinges on decisive yet careful implementation. The Federal Council has set the course – now it’s up to regulators, industry, and the expert community to follow through. 

Conclusion: 2028 Is Realistic – and Pivotal 

Ralph Nowak, Partner at Winterberg Group AG, summarizes: “After thorough analysis of the regulatory roadmap, international comparison data, and involved processes, the conclusion is clear and well-founded: initial market access can be expected in the first half of 2028.” 

Fabian Kroeher, Partner at Winterberg Group AG, adds: “This timeline is realistic, though ambitious. It requires that political processes are not blocked, that Swissmedic accredits CABs quickly, and that manufacturers are ready to submit their dossiers promptly. A launch before the end of 2027 is conceivable – but only under optimal conditions. Delays until 2029 are possible if political or technical hurdles arise.” 

For Switzerland, 2028 is thus a target year of major significance. If the opening to FDA products succeeds, it could not only close supply gaps but also serve as a model for other small, innovation-friendly countries. 

As of early April 2025, transaction activity in the European healthcare and medical technology sector continues to reflect several themes that validate Winterberg Group’s investment strategy. The first quarter highlights how consolidation, asset-light platforms, demographic tailwinds, and aligned governance structures are reshaping value creation across public and private markets. Ralph Nowak, Partner at Winterberg Group states: “Notably, the executional relevance of these themes is apparent in our portfolio company Healthcare Holding Schweiz AG, which continues to scale via strategic acquisitions in the Swiss MedTech and regulatory services ecosystem.” 

Key Market Trends Relevant to Winterberg’s Strategy 

Consolidation as a Value Driver 

Private equity investors remain focused on fragmented niches such as digital dentistry, MedTech distribution, and regulatory compliance. This trend is visible across several recent transactions, including our own acquisitions through Healthcare Holding Schweiz, as well as platforms developed by peers such as LBO France (Hemodia) and KKA Partners (BLACKROLL). These investments emphasize vertically integrated, sector-specific roll-up strategies—consistent with Winterberg’s “Buy, Build & Technologize” approach. 

Asset-Light Models Rewarded by Public Markets 

The IPO of Asker Healthcare Group AB underscores investor appetite for scalable, asset-light distribution platforms with high cash conversion and low capex intensity. With a current EV/EBITDA multiple of 24.1x, Asker’s market reception validates our thesis behind Healthcare Holding Schweiz: value accrues to those who can consolidate fragmented supply chains, optimize procurement, and build regulatory and digital capabilities into their platforms. 

Thematic and Demographic Tailwinds 

Funds like Quadrivio’s Silver Economy Fund demonstrate the power of long-term demographic alignment, particularly with aging populations and preventive healthcare. This reinforces Winterberg’s continued interest in healthcare adjacencies with strong macro tailwinds and resilience to economic cycles. 

Alignment Through Equity Participation 

Whether through equity rollovers (e.g., Dental Axess) or management buyouts (e.g., BLACKROLL), governance structures that align operators with institutional capital remain critical. Winterberg follows this principle in structuring equity incentives for management teams across our platforms, ensuring long-term executional focus. 

 

Portfolio Execution: Healthcare Holding Schweiz AG 

Acquisition of Effectum CH-Rep AG (Switzerland, March 2025) 

Through Healthcare Holding Schweiz AG, we acquired Effectum CH-Rep AG, the Swiss Authorized Representative (CH-REP) carve-out from Effectum Medical AG. The company provides critical regulatory infrastructure for non-EU MedTech companies accessing the Swiss market, including liaison with Swissmedic, PRRC appointment, and incident management. 

This acquisition deepens our capabilities in regulatory compliance, a core pillar in our platform’s full-service value proposition. Effectum CH-Rep’s integration enables us to offer end-to-end support to foreign device manufacturers—combining import, distribution, and regulatory functions under one roof. 

Acquisition of Dental Axess AG (Switzerland, March 2025) 

Mikrona Group AG, a Healthcare Holding subsidiary, completed the buyout of Dental Axess AG, focusing on its Swiss operations in digital dental technology. Dental Axess strengthens our position in digital dentistry by adding CAD/CAM systems, scanners, and software tools to our portfolio. The deal was structured as a carve-out, with international activities remaining under Dental Axess Holding AG. 

As part of the transaction, Dental Axess AG’s Managing Director joined the shareholder group of Healthcare Holding Schweiz, creating clear alignment on growth and integration objectives. 

 

Relevant Market Activity Across Europe 

Winterberg and Dealert actively track transactions that shape the European healthcare landscape. Several recent deals offer benchmarks and strategic insights: 

Investment of Fagerhult Group into Trato TLV Group in a Strategic Partnership deal, France (04/04/2025) 

As of April 4th, 2025, Fagerhult Group announced that it has entered into an agreement to acquire 100% of the shares in the Trato TLV Group, including Trato SAS and its subsidiaries Trato Industries SAS, T.L.V. SAS, and Biolume Sarl. The Trato TLV Group, headquartered in Lille, France, operates across three sites and comprises three distinct brands with established reputations in retail and infrastructure lighting (Trato) as well as healthcare equipment (TLV and Biolume). 

The Group reported total revenue of €56 million for the year 2024, split between Trato (€36 million) and TLV/Biolume (€20 million), and employs 230 individuals. The transaction, scheduled to close in Q2 2025, is being financed through a mix of existing cash reserves and new credit facilities. 

On a pro forma basis, the acquisition will increase Fagerhult’s Net Debt/EBITDA from 2.00x to 2.55x, while contributing a 0.4% increase to the Group’s operating margin. Although valuation multiples have not been disclosed, the deal represents a strategic consolidation in the French lighting and healthcare equipment sectors. 

Regulatory and labor body approvals remain outstanding. The Picha family, current owners, are retaining involvement, supporting operational continuity post-close. No exit strategy has been specified at this stage. 

Read more here: https://dealert.ai/deal_public?id=2XE9  

Investment of Silver Economy Fund into Biotec Italia in a Majority Stake Acquisition, Italy (29/03/2025) 

As of March 29th, 2025, Silver Economy Fund, a thematic private equity fund managed by Quadrivio Group, announced that it acquired a majority stake in Biotec Italia, a leading Italian provider of non-invasive technological solutions for aesthetic medicine. 

Founded in 1993 and headquartered in Dueville, Vicenza, Biotec Italia specializes in the development and commercialization of Energy-Based Devices (EBD), leveraging a suite of patented technologies including lasers, ultrasound, microwaves, and cryotherapy systems. The company operates in over 60 countries, with Italy accounting for 53% of device sales—handled through direct channels—while international sales are managed via distributors. Key markets include Poland, Brazil, France, Hong Kong, Germany, and others. 

In FY2024, Biotec Italia recorded €18 million in revenue, with 15% derived from aesthetic product lines complementary to its device offerings. Over 30,000 devices have been sold globally. Production is entirely in Italy, adhering to ISO 13485 standards, with in-house capabilities ensuring end-to-end quality control. 

The acquisition marks the fund’s fifth investment in Silver Economy’s sector, aligning with its thematic focus on products and services for aging populations. No valuation or exit timeline has been disclosed. 

Read more here: https://dealert.ai/deal_public?id=J5JJ 

Investment of LBO France into Hemodia in a Management Buyout Deal, France (27/03/2025) 

As of March 27, 2025, LBO France has acquired a majority stake in Hemodia, a leading French manufacturer of single-use medical and electro-medical devices. Established in 1985, Hemodia designs and produces treatment sets primarily for dialysis and infusion, as well as pumps and tubing for arthroscopy used in minimally invasive surgical procedures. Headquartered in Toulouse, the company operates five production facilities across France and Tunisia, all equipped with advanced sterilization systems and logistics infrastructure tailored to meet stringent healthcare standards. Hemodia employs around 500 staff and reported annual revenues of approximately €50 million, supported by an 8% average annual growth rate. The company holds a strong market position in high-demand segments such as dialysis in France and arthroscopic devices, bolstered by in-house R&D capabilities and internally developed technological solutions. Rothschild & Co advised on the transaction. 

Hemodia’s alignment with ESG principles—through investments in recyclable materials, packaging reduction, and sustainable sterilization processes—adds strategic value, reinforcing its operational resilience and compliance with evolving sector standards. While no transaction valuation or exit timeline has been disclosed, the deal reflects LBO France’s continued emphasis on healthcare sector investments characterized by operational excellence, defensible market positions, and scalability within regulated environments. 

Read more here: https://dealert.ai/deal_public?id=JTT2  

Investment of Teleflex Incorporated into the Vascular Intervention Division of BIOTRONIK in a Strategic Partnership Deal, Germany (27/02/2025) 

As of February 27, 2025, BIOTRONIK, a German-based leader in medical technology, announced that it agreed to divest its Vascular Intervention (VI) division to Teleflex Incorporated (NYSE: TFX), a global medical device company. The transaction is expected to close by Q3 2025, pending regulatory approval. 

This strategic divestiture allows BIOTRONIK to focus its resources on its core competencies in active implantable devices and digital healthcare technologies. The VI division includes a portfolio of advanced interventional therapies, including drug-eluting stents and vascular scaffolds, which strategically complement Teleflex’s existing interventional business. 

The deal highlights BIOTRONIK’s longstanding reputation for innovation and quality across the cardiovascular, endovascular, and neuromodulation markets. While no financial metrics or valuation multiples were disclosed, the acquisition aligns with Teleflex’s broader strategy to expand its global capabilities in delivering high-impact healthcare solutions. 

Although the transaction is subject to regulatory approval, it offers strong strategic rationale for both parties. The sale supports BIOTRONIK’s capital reallocation toward areas such as Cardiac Rhythm Management, Patient Monitoring, Heart Failure, and Neuromodulation—sectors aligned with macro healthcare trends emphasizing digital innovation and specialized implantable technologies. 

Read more here: https://dealert.ai/deal_public?id=RF2J  

Investment of KKA Partners into BLACKROLL in a Management Buyout Deal, Switzerland (31/01/2025) 

On January 31, 2025, BLACKROLL, a global leader in health and recovery products based in Switzerland, announced the completion of a management buyout (MBO) led by private equity firm KKA Partners. The transaction follows a record financial year for BLACKROLL in 2024. 

Specific financial details such as revenue, EBITDA, transaction size, or valuation multiples were not disclosed. The MBO includes both leadership continuity and organizational restructuring. 

Founded in 2007, BLACKROLL serves over 57 international markets with a range of products focused on physical recovery, movement, and sleep enhancement. Its offerings are rooted in applied expertise from physiotherapy, sports science, and medicine. 

The company operates within the broader Swiss health and wellness industry, which continues to benefit from strong consumer demand, quality-focused regulation, and innovation in recovery and rehabilitation products. BLACKROLL is distinguished by its emphasis on sustainability and premium brand positioning. 

No information has been provided regarding the capital structure post-transaction, return expectations, intended investment duration, or exit strategy. The investment thesis is supported by BLACKROLL’s strong brand, established global presence, and role as a leader in an expanding segment of the wellness market. 

Read more here: https://dealert.ai/deal_public?id=U9LH  

Investment of Silver Economy Fund into Medical International Research in a Buyout Deal, Italy (29/01/2025) 

As of January 29, 2025, the Silver Economy Fund, a private equity vehicle managed by Quadrivio Group, completed the acquisition of 100% of MIR (Medical International Research), a Rome-based global leader in spirometry diagnostics. Founded in 1993, MIR develops and distributes medical devices and proprietary software for the diagnosis and monitoring of respiratory conditions. Its product portfolio includes spirometers, pulse oximeters, and disposable respiratory turbines, integrated with real-time monitoring software. 

MIR’s international regulatory certifications—including approvals from the FDA, NMPA, ANVISA, COFEPRIS, and Health Canada—enable its products to be marketed globally. The company maintains a presence in over 100 countries through direct subsidiaries in North America, France, and Brazil, supported by a robust distribution network. 

MIR reported €22 million in revenue for 2024, doubling from €11 million in 2020, reflecting an approximate compound annual growth rate (CAGR) of 20%. This growth underscores the company’s scalability and market penetration in a sector benefiting from strong tailwinds, including rising awareness of respiratory health and increased demand for diagnostic solutions. 

The spirometry market itself is valued at over €1 billion and is projected to reach €1.8 billion by 2031, driven by demographic trends and technological innovation in healthcare. The transaction structure, valuation, and leverage levels were not disclosed. Nonetheless, MIR’s global footprint, strong compliance infrastructure, and consistent revenue growth make it a compelling asset within the expanding respiratory diagnostics market. 

Read more here: https://dealert.ai/deal_public?id=LXX9 

Investment of KARL STORZ into ANKLIN in a Buyout Deal, Switzerland (20/01/2025) 

As of January 15, 2025, KARL STORZ, a global leader in endoscopic and minimally invasive surgical technologies, completed the acquisition of ANKLIN, its long-standing Swiss distribution partner. 

The transaction involves the full transfer of ANKLIN’s product sales and service operations related to KARL STORZ, along with approximately 80 employees who have been dedicated to supporting KARL STORZ accounts. Although the financial terms of the deal were not disclosed, this acquisition is consistent with KARL STORZ’s broader strategy of transitioning to direct sales in key European markets. 

ANKLIN, which has established a strong market share and is highly regarded for its customer service and efficient delivery, will continue to operate under its brand name from its current facility in Reinach, Switzerland. Importantly, the portion of ANKLIN’s business unrelated to KARL STORZ was spun off prior to the transaction. 

The acquisition is expected to strengthen KARL STORZ’s market position in Switzerland by improving operational control, ensuring continuity of customer relationships, and leveraging ANKLIN’s deep local expertise. KARL STORZ plans to incorporate ANKLIN into its broader European organizational framework to drive alignment across key regional markets. 

The deal also reflects a broader trend of vertical integration within the high-value MedTech market. 

Read more here: https://dealert.ai/deal_public?id=BTEC  

IPO of Asker Healthcare Group AB on the Stockholm Stock Exchange, Sweden (27/03/2025) 

Asker Healthcare Group AB (publ), a leading B2B provider of medical technology supplies and services in Europe, completed its initial public offering on March 27, 2025, listing its shares on Nasdaq Stockholm. Headquartered in Danderyd, Sweden, the company operates through 45 subsidiaries across 17 European countries, with over 4,000 employees. It supplies healthcare institutions—including hospitals, elderly and homecare providers, and public health authorities—with a wide array of consumables, devices, equipment, and value-added services. These include procurement support, IT integration, logistics coordination, product bundling, and administrative and patient support services. 

Positioned at the center of the MedTech distribution value chain, Asker bridges the gap between fragmented suppliers and care providers, streamlining product access and enhancing procurement efficiency. Asker’s economic moat stems from its role as a consolidator in Europe’s fragmented MedTech distribution sector, where its integrated procurement, logistics, and compliance infrastructure enables smaller acquired firms to meet complex regulatory, ESG, and tendering requirements that would otherwise limit their competitiveness in institutional healthcare markets. 

For the year ending December 31, 2024, Asker generated SEK 15,025 million in revenue and SEK 1,466 million in EBITDA, equating to an EBITDA margin of 9.8%. The company’s asset-light structure and operational design enabled an average cash conversion rate of 89% from 2022 to 2024, underpinned by disciplined working capital management and a low capex profile (1.5–2% of sales). On IPO day, Asker’s market capitalization stood at SEK 26.8 billion—representing the total market value of all shares assuming full subscription of the offering—while net debt was SEK 3.091 billion, leading to an enterprise value (EV) of SEK 29.891 billion and an EV/EBITDA multiple of 20.4x based on the latest reported figures. By April 8, the EV had increased to SEK 35.27 billion, reflecting a 24.1x EV/EBITDA multiple. 

The offering comprised approximately 127 million shares (33% of the company), of which 21.4 million were newly issued, raising SEK 1.5 billion in gross proceeds. SEK 1.2 billion of the proceeds were used to refinance credit facilities, materially strengthening the balance sheet and reducing leverage. The remaining SEK 235 million was designated for bolt-on acquisitions and equity investments in target companies. Notably, a 15% over-allotment option—equal to 19 million additional shares—was exercised in full following high demand, increasing the free float and solidifying aftermarket trading liquidity. The transaction attracted strong interest from both Nordic retail investors and global institutions, and no price stabilization measures were needed post-listing, with shares rising up to 25% above IPO price on debut. 

Key pre-IPO events include the February 2025 acquisitions of two companies with a combined SEK 860 million in revenue and SEK 110 million in EBITDA, as well as a March 2025 share issue of 20.5 million shares to settle shareholder loans, optimizing capital structure prior to listing. The offering was Europe’s largest IPO of 2025 to date and followed the earlier IPO of Roko AB, reflecting strong market appetite for scaled, cash-generative healthcare platforms. 

Asker Healthcare Group AB IPO Implications for Healthcare Holding Schweiz AG 

Asker Healthcare’s IPO, now trading at a 24.1x EV/EBITDA multiple as of April 8, 2025, highlights a broad re-rating in the valuation of scaled MedTech distribution platforms in Europe. This upward shift in market expectations affirms the attractiveness of centralized, asset-light operating models that unlock margin and working capital efficiency across fragmented supply chains—a dynamic directly relevant to Healthcare Holding Schweiz AG. 

Asker’s positioning confirms that buyers are paying a premium for platforms that can consolidate procurement volume, reduce supplier complexity for care providers, and generate cash from low-capex operations. 

For Healthcare Holding, this underscores that executing its roll-up strategy in Switzerland—by integrating smaller distributors under a unified logistics and sourcing structure—can directly translate into higher enterprise value per acquired unit.  

 

Winterberg’s partnership with Dealert 

In March 2025, Winterberg Group AG announced a strategic partnership with Dealert.AI, a leading AI-powered M&A transaction database. This collaboration aims to enhance Winterberg’s investment operations by leveraging Dealert.AI’s extensive deal data and artificial intelligence capabilities. Together, the firms plan to co-develop proprietary AI tools designed to optimize deal sourcing, market mapping, competitor analysis, and the evaluation of large datasets. These initiatives are intended to strengthen Winterberg’s market presence and drive technological innovation across its portfolio companies. Additionally, Winterberg will utilize Dealert.AI’s comprehensive database to publish in-depth transaction insights in its core sectors, including Healthcare, MedTech, and Testing, Inspection & Certification (TIC), thereby reinforcing its commitment to transparency and data-driven decision-making in the European private equity landscape. 

Healthcare Holding Schweiz AG, a leading provider of services and distributor of medical technology in Switzerland, has expanded its portfolio with the acquisition of Ino Medical Solutions GmbH. Healthcare Holding Schweiz is managed by Winterberg Advisory GmbH and KKA Partners. 

Baar, Switzerland – June 2025 

Healthcare Holding Schweiz AG has successfully completed the acquisition of Ino Medical Solutions GmbH, based in Rapperswil-Jona. Ino Medical is a specialized provider of sterile containers, medical instruments, and implants, serving sterilization centers, university and cantonal hospitals, as well as private hospital groups across Switzerland. 

Fabian Kröher, Chairman of the Board of Healthcare Holding Schweiz AG and Partner at Winterberg, commented: “Ino Medical Solutions is a leading Swiss player in the sterile container segment, offering the best product in the market. In daily sterilization workflows, stability, safety, and ease of use are key — particularly in larger hospital systems or when sterilization is outsourced to dedicated centers and transport routes become longer. We will leverage the full strength of our holding to further accelerate Ino’s successful market development.” 

Dieter Roth, Managing Director of Ino Medical Solutions, added:“Healthcare Holding Schweiz was my preferred partner for succession. I am fully confident that Ino Medical Solutions is in the best, capable hands, and so are all our customers and suppliers. I will continue to be actively involved in the business for the foreseeable future, so we can continue to grow the market together — not only for sterile containers, but also for instruments and implants. I very much look forward to this collaboration.” 

 

About Ino Medical Solutions GmbH

 

Based in Rapperswil-Jona, Ino Medical Solutions GmbH is a specialist provider of sterile containers, surgical instruments, explantation tools, spinal implants, and other products, acting as exclusive distributor in Switzerland for renowned international manufacturers. The company’s products meet the highest quality standards and are considered among the best in the market. Ino Medical Solutions is also recognized for its market-leading turnaround and delivery times, as well as outstanding customer service. 

 

About Healthcare Holding Schweiz AG 

 

Healthcare Holding Schweiz AG is a Buy, Build & Technologize platform and a leading provider of medical technology products and services in Switzerland. The group is based in Baar and pursues an ambitious growth strategy through acquisitions, often in the context of succession arrangements, partnerships, and organic growth. Healthcare Holding Schweiz and its group companies are committed to the highest standards of innovation and customer satisfaction. The group consistently leverages technology to make business processes safer and more efficient. As a market leader, the company sets new standards for the industry and offers employees attractive development opportunities. All of the management team holds shares in Healthcare Holding Schweiz, thus forming a dynamic community of entrepreneurs. Since 2023, the group has been led by CEO Fabio Fagagnini. 

 

About KKA Partners 

 

Founded in 2018, KKA Partners is a Berlin-based lower mid-market private equity firm that invests in leading companies in Germany, Austria and Switzerland – the so-called “Mittelstand”. The Founding Partners all have a deep-rooted family and professional heritage in the Mittelstand developed over 20 years in working closely with Mittelstand companies. KKA is at the forefront of the next wave of value creation through Technology Enabled Transformation of the Mittelstand. 

 

About Winterberg Advisory GmbH and Winterberg Group AG 

 

Winterberg Group AG, based in Zug, operates as an independent family office for its founders. Winterberg mainly invests in SMEs in the German-speaking region and selectively considers investments in startups and real estate. Winterberg Advisory GmbH is a general partner and fund manager regulated by the German BaFin. Winterberg Advisory has launched numerous private equity funds and is invested in Healthcare Holding Schweiz AG through its funds Winterberg Investment VIII and Winterberg Investment IX. The two Partners and Executive Directors, Fabian Kröher and Florian Brickenstein, manage Healthcare Holding Schweiz AG via its board of directors. 

 

For press inquiries, please contact presse@healthcare-holding.ch 

Note for Editors: Please reference Healthcare Holding Schweiz AG for any provided quotes and information. 

For more information about Ino Medical Solutions GmbH, visit www.inomedicalsolutions.ch  

For more information about Healthcare Holding Schweiz AG, visit www.healthcare-holding.ch  

For more information about the portfolio companies of Healthcare Holding, visit www.senectovia.ch, www.winthermedical.ch, www.mikrona.ch, www.orthowalker.ch, www.mcm-medsys.ch, www.naropa-reha.ch, www.mvb-medizintechnik.ch, www.dentalaxess.com, www.effectum-chrep.com, www.schaublin-medica.ch, www.cdpswiss.com, www.aestheticbedarf.ch 

For more information about KKA Partners visit www.kkapartners.com and about Winterberg www.winterberg.group. 

This press release is issued and distributed by Winterberg Advisory GmbH on behalf of Healthcare Holding Schweiz AG. 

Healthcare Holding Schweiz AG, a leading provider of services and distributor of medical technology in Switzerland, has expanded its portfolio with the acquisition of Aestheticbedarf AG. Healthcare Holding Schweiz is managed by Winterberg Advisory and KKA Partners. 

Baar, Switzerland – April 2025 

Healthcare Holding Schweiz AG has successfully closed the acquisition of Aestheticbedarf AG, headquartered in Affoltern, an ISO-certified company specializing in exclusive yet affordable branded products for aesthetic applications. Their extensive portfolio features solutions such as hyaluronic treatments, laser systems, IPL, microneedling, cryolipolysis, mesotherapy, radiofrequency, deep cleansing technologies, and consumables. 

Fabian Kröher, Chairman of the Board at Healthcare Holding Schweiz and Partner at Winterberg, shared his excitement: “Aestheticbedarf AG strengthens our newly established Medical Beauty platform alongside CDP Swiss AG and CDP Austria GmbH. With its philosophy that quality does not always have to be expensive, the company reaches a wide range of users across Switzerland. We are thrilled to launch this segment with full force, backed by now three portfolio companies.”  

Pascal Hauser, Managing Director of Aestheticbedarf AG, added: “We look forward to an exciting collaboration within the group. Without a doubt, we will continue our success story together with Healthcare Holding Schweiz – the entire team is highly motivated! By joining forces with other companies in the group, we will deliver even better offerings to our customers.” 

 

About Aestheticbedarf AG 

Aestheticbedarf AG, based in Affoltern am Albis, represents exceptional progress in aesthetic treatment technologies. The company exclusively distributes products that meet rigorous Swiss and European standards, including devices for treatments such as hyaluronic applications, laser systems, IPL, microneedling, cryolipolysis, mesotherapy, radiofrequency, deep cleansing technologies, and consumables. Its focus lies on offering affordable, high-quality branded products. Sustainability and forward-thinking technological advancements remain the company’s top priorities. 

 

About Healthcare Holding Schweiz AG 

Healthcare Holding Schweiz AG is a Buy, Build & Technologize platform and a leading provider of medical technology products and services in Switzerland. The group is based in Baar and pursues an ambitious growth strategy through acquisitions, often in the context of succession arrangements, partnerships, and organic growth. Healthcare Holding Schweiz and its group companies are committed to the highest standards of innovation and customer satisfaction. The group consistently leverages technology to make business processes safer and more efficient. As a market leader, the company sets new standards for the industry and offers employees attractive development opportunities. All of the management team holds shares in Healthcare Holding Schweiz, thus forming a dynamic community of entrepreneurs. Since 2023, the group has been led by CEO Fabio Fagagnini. 

 

About KKA Partners

Founded in 2018, KKA Partners is a Berlin-based lower mid-market private equity firm that invests in leading companies in Germany, Austria and Switzerland – the so-called “Mittelstand”. The Founding Partners all have a deep-rooted family and professional heritage in the Mittelstand developed over 20 years in working closely with Mittelstand companies. KKA is at the forefront of the next wave of value creation through Technology Enabled Transformation of the Mittelstand.

 

About Winterberg Advisory GmbH and Winterberg Group AG 

Winterberg Group AG, based in Zug, operates as an independent family office for its founders. Winterberg mainly invests in SMEs in the German-speaking region and selectively considers investments in startups and real estate. Winterberg Advisory GmbH is a general partner and fund manager regulated by the German BaFin. Winterberg Advisory has launched numerous private equity funds and is invested in Healthcare Holding Schweiz AG through its funds Winterberg Investment VIII and Winterberg Investment IX. The two Partners and Executive Directors, Fabian Kröher and Florian Brickenstein, manage Healthcare Holding Schweiz AG via its board of directors. 

 

For press inquiries, please contact presse@healthcare-holding.ch 

Note for Editors: Please reference Healthcare Holding Schweiz AG for any provided quotes and information. 

For more information about Aestheticbedarf AG, visit www.aestheticbedarf.ch 

For more information about Healthcare Holding Schweiz AG, visit www.healthcare-holding.ch  

For more information about the portfolio companies of Healthcare Holding, visit www.senectovia.ch, www.winthermedical.ch, www.mikrona.ch, www.orthowalker.ch, www.mcm-medsys.ch, www.naropa-reha.ch, www.mvb-medizintechnik.ch, www.dentalaxess.com, www.effectum-chrep.com, www.schaublin-medica.ch, www.cdpswiss.com 

For more information about KKA Partners visit www.kkapartners.com and about Winterberg www.winterberg.group.

This press release is issued and distributed by Winterberg Advisory GmbH on behalf of Healthcare Holding Schweiz AG. 

 

Healthcare Holding Schweiz AG, a leading provider of services and distributor of medical technology in Switzerland, has expanded its portfolio by acquiring CDP Swiss AG and CDP Austria GmbH. Healthcare Holding Schweiz is managed by Winterberg Advisory and KKA Partners. 

Baar, Switzerland – April 2025 

Healthcare Holding Schweiz AG has successfully closed the acquisition of CDP Swiss AG, based in Affoltern, and its subsidiary, CDP Austria GmbH, located in Lustenau. CDP Swiss AG is an ISO-certified, multi-brand company renowned for offering the most extensive and innovative product range in the Swiss medical aesthetics market. Their portfolio includes a wide array of advanced medical laser systems, microneedling devices, cryolipolysis, light therapy, ultrasound, shockwave technologies, and exclusive dermaceutical product lines. Complementing this is a dedicated service department that ensures comprehensive support for clients. Regular training sessions and expert consultations help customers excel in every aspect of their businesses. 

Fabio Fagagnini, CEO of Healthcare Holding Schweiz, expressed his enthusiasm about this acquisition: “By acquiring CDP Swiss AG, we are bringing on board the undisputed Swiss market leader in the field of medical beauty. This allows us to establish a dynamic and fast-growing platform within our group, catering to both medical and cosmetic practitioners with exceptional care.” 

Falk Dörstling, Founder and Chairman of the Board at CDP Swiss AG, commented: “With our extensive product portfolio and outstanding service, we have achieved market leadership in Switzerland. For our next growth phase, we’ve partnered with a strong group whose synergies and investments will propel us to even greater heights.” 

Burim Hasani, Co-Founder and Managing Director of CDP Swiss AG, added: “What impressed us most about Healthcare Holding Schweiz is their commitment to quality and professionalism – values that perfectly align with those of our own company. Together, we will enhance our customer offerings further and continue our remarkable growth journey.”

 

About CDP Swiss AG and CDP Austria GmbH 

CDP Swiss AG, headquartered in Affoltern, exemplifies innovation and excellence in the field of medical beauty. The company exclusively distributes premium-quality, certified products that meet the rigorous Swiss and European standards. Their extensive portfolio encompasses cutting-edge medical laser systems, microneedling technology, cryolipolysis, light therapy, ultrasound, shockwave treatments, and exclusive dermaceutical product lines. A dedicated team of field and customer service professionals, well-versed in the latest industry innovations, solidifies CDP Swiss AG’s position as the market leader in Switzerland. The newly established CDP Austria GmbH addresses the growing demand from the EU region, delivering the same exceptional CDP quality. 

 

About Healthcare Holding Schweiz AG 

Healthcare Holding Schweiz AG is a Buy, Build & Technologize platform and a leading provider of medical technology products and services in Switzerland. The group is based in Baar and pursues an ambitious growth strategy through acquisitions, often in the context of succession arrangements, partnerships, and organic growth. Healthcare Holding Schweiz and its group companies are committed to the highest standards of innovation and customer satisfaction. The group consistently leverages technology to make business processes safer and more efficient. As a market leader, the company sets new standards for the industry and offers employees attractive development opportunities. All of the management team holds shares in Healthcare Holding Schweiz, thus forming a dynamic community of entrepreneurs. Since 2023, the group has been led by CEO Fabio Fagagnini. 

 

About KKA Partners

Founded in 2018, KKA Partners is a Berlin-based lower mid-market private equity firm that invests in leading companies in Germany, Austria and Switzerland – the so-called “Mittelstand”. The Founding Partners all have a deep-rooted family and professional heritage in the Mittelstand developed over 20 years in working closely with Mittelstand companies. KKA is at the forefront of the next wave of value creation through Technology Enabled Transformation of the Mittelstand.

 

About Winterberg Advisory GmbH and Winterberg Group AG 

Winterberg Group AG, based in Zug, operates as an independent family office for its founders. Winterberg mainly invests in SMEs in the German-speaking region and selectively considers investments in startups and real estate. Winterberg Advisory GmbH is a general partner and fund manager regulated by the German BaFin. Winterberg Advisory has launched numerous private equity funds and is invested in Healthcare Holding Schweiz AG through its funds Winterberg Investment VIII and Winterberg Investment IX. The two Partners and Executive Directors, Fabian Kröher and Florian Brickenstein, manage Healthcare Holding Schweiz AG via its board of directors. 

 

For press inquiries, please contact presse@healthcare-holding.ch. 

Note for Editors: Please reference Healthcare Holding Schweiz AG for any provided quotes and information. 

For more information about CDP Swiss AG, visit www.cdpswiss.com. 

For more information about Healthcare Holding Schweiz AG, visit www.healthcare-holding.ch. 

For more information about the portfolio companies of Healthcare Holding, visit www.senectovia.ch, www.winthermedical.ch, www.mikrona.ch, www.orthowalker.ch, www.mcm-medsys.ch, www.naropa-reha.ch, www.mvb-medizintechnik.ch, www.dentalaxess.com, www.effectum-chrep.com, www.schaublin-medica.ch

For more information about KKA Partners visit www.kkapartners.com and about Winterberg www.winterberg.group.

This press release is issued and distributed by Winterberg Advisory GmbH on behalf of Healthcare Holding Schweiz AG. 

Healthcare Holding Switzerland AG, a leading provider of services and distributor of medical technology in Switzerland, has strengthened its portfolio with the acquisition of Schaublin Medica SA. Healthcare Holding Switzerland is managed by Winterberg Advisory GmbH. 

Baar, Switzerland – April 2025 

Healthcare Holding Switzerland AG has successfully completed the acquisition of Schaublin Medica SA. As part of a succession plan, the group acquired 100% of the shares from the founders. Schaublin Medica specializes in the distribution of vascular grafts, endoprostheses, stents, and drug-coated balloon catheters from leading manufacturers to hospitals across Switzerland. In addition to offering high-quality products, the company provides consulting, training, and service solutions. Its founder, Robert Schäublin, has over 40 years of expertise in cardiac and vascular surgery. 

David Egger, a member of the management team at Healthcare Holding Switzerland, expressed his enthusiasm for the acquisition:  ”Schaublin Medica is a highly reputable and well-known specialist provider of products for invasive and endovascular procedures across Switzerland. The company embodies excellence in medical technology and exceptional customer service. We are committed to reliably and responsibly continuing the successful development and operation of Schaublin Medica.” 

Robert Schäublin, founder and President of the Board of Directors of Schaublin Medica SA, added:  ”We are truly delighted to have found the ideal partner for the succession of our company. I will continue to dedicate myself to my work with great passion and remain involved in the business. It’s reassuring to know that Schaublin Medica’s team and customers are in capable hands. Together with the other companies in the group, we will have the opportunity to expand our product portfolio and deliver even greater service excellence to our clients.”

 

About Schaublin Medica SA 

Based in Plan-les-Ouates, Schaublin Medica SA is a specialized distributor in cardiac and vascular surgery, offering vascular grafts, endoprostheses, stents, and balloon catheters. The company exclusively represents reliable and globally established suppliers who remain at the forefront of research and continuously advance their technologies. Schaublin Medica places the utmost importance on personalized consultation, reliability, and flexibility for its customers.

 

About Healthcare Holding Schweiz AG 

Healthcare Holding Schweiz AG is a Buy, Build & Technologize platform and a leading provider of medical technology products and services in Switzerland. The group is based in Baar and pursues an ambitious growth strategy through acquisitions, often in the context of succession arrangements, partnerships, and organic growth. Healthcare Holding Schweiz and its group companies are committed to the highest standards of innovation and customer satisfaction. The group consistently leverages technology to make business processes safer and more efficient. As a market leader, the company sets new standards for the industry and offers employees attractive development opportunities. All of the management team holds shares in Healthcare Holding Schweiz, thus forming a dynamic community of entrepreneurs. Since 2023, the group has been led by CEO Fabio Fagagnini.

 

About KKA Partners

Founded in 2018, KKA Partners is a Berlin-based lower mid-market private equity firm that invests in leading companies in Germany, Austria and Switzerland – the so-called “Mittelstand”. The Founding Partners all have a deep-rooted family and professional heritage in the Mittelstand developed over 20 years in working closely with Mittelstand companies. KKA is at the forefront of the next wave of value creation through Technology Enabled Transformation of the Mittelstand.

 

About Winterberg Advisory GmbH and Winterberg Group AG 

Winterberg Group AG, based in Zug, operates as an independent family office for its founders. Winterberg mainly invests in SMEs in the German-speaking region, and selectively considers investments in startups and real estate. Winterberg Advisory GmbH is a general partner and fund manager regulated by the German BaFin. Winterberg Advisory has launched numerous private equity funds and is invested in Healthcare Holding Schweiz AG through its funds Winterberg Investment VIII and Winterberg Investment IX. The two Partners and Executive Directors, Fabian Kröher and Florian Brickenstein, manage Healthcare Holding Schweiz AG via its board of directors. 

For press inquiries, please contact presse@healthcare-holding.ch. 

Note for Editors: Please reference Healthcare Holding Schweiz AG for any provided quotes and information. 

For more information about Schaublin Medica SA, visit www.schaublin-medica.ch. 

For more information about Healthcare Holding Schweiz AG, visit www.healthcare-holding.ch. 

For more information about the portfolio companies of Healthcare Holding, visit www.senectovia.ch, www.winthermedical.ch, www.mikrona.ch, www.orthowalker.ch, www.mcm-medsys.ch, www.naropa-reha.ch, www.mvb-medizintechnik.ch, www.dentalaxess.com, www.effectum-chrep.com.

For more information about KKA Partners visit www.kkapartners.com and about Winterberg Advisory GmbH www.winterberg.group.

This press release is issued and distributed by Winterberg Advisory GmbH on behalf of Healthcare Holding Schweiz AG. 

Dealert.AI, an emerging AI-enhanced global M&A transactions database, and Winterberg Group AG, a private equity firm specializing in Buy, Build and Technologize investments in the SME sector in Germany, Switzerland and Austria, have announced a strategic partnership aimed at leveraging Dealert’s extensive deal data and AI capabilities to strengthen Winterberg’s market presence as well as technological innovation and specifically to develop prioprietory AI-based tools together. 

Zug, Switzerland – March 2025 

Dealert.AI is the world’s most comprehensive M&A deal database. Its global dataset is updated daily with transactions of all types, sizes, industries and regions solely by AI. Users benefit from receiving structured data on transactions, as well as email alerts for specific companies, industries or regions on request. 

Through this partnership, Winterberg will utilize Dealert’s comprehensive database to share deep insights on M&A transactions in its core target markets, including Switzerland, Healthcare, MedTech, and Testing, Inspection & Certification (TIC). These insights will be published on a regular basis to inform Winterberg’s investors, employees and the general public about its activies and SMEs in general, underlining Winterberg’s ambition to thought leadership and innovation in the European private equity landscape. 

In addition to delivering M&A insights, Dealert and Winterberg will jointly develop advanced AI tools designed to foster innovation and optimize both Winterberg’s investment operations and the performance of its portfolio companies. These tools will focus on deal and customer sourcing, market mapping, competitor analysis and analysis of large data sets.  

Fabian Kröher, Executive Director at Winterberg Group AG, commented: “At Winterberg, we believe innovation is key to maintaining our competitive edge. This partnership with Dealert not only enriches our market intelligence but also empowers us to integrate cutting-edge AI tools into many aspects of our operations and portfolio management. We really believe that transparency and strictly data-driven business processes drive long-term value in our portfolio as well as in Winterberg itself.” 

Gregory Budakow, Founder of Dealert, added: “Being part of Winterberg’s core investment team for almost a decade, I have been building many of its key processes. Now I am excited to collaborate with Winterberg on another, additional level. This partnership is a powerful opportunity to demonstrate how AI solutions can drive real innovation in private equity and transform how firms source deals, make decisions, and scale platforms.”

 

About Dealert.AI 

Dealert.AI is a global M&A database tracking transactions across all market segments and geographies. Dealert aims to democratize access to M&A deal knowledge and reduce reliance on expensive enterprise software. The platform serves investment professionals, bankers, M&A advisors, consultants, and researchers seeking comprehensive and actionable deal intelligence.  

 

About Winterberg Group AG 

Winterberg Group AG, based in Zug, operates as an independent family office for its founders. The firm focuses on investing in small and medium-sized enterprises (SMEs) in the German-speaking region, with particular expertise in succession solutions, sustainable growth, and innovation leadership. Winterberg also selectively invests in startups and real estate. Its fund management arm, Winterberg Advisory GmbH, is regulated by the German BaFin and manages several private equity funds, including investments in Healthcare Holding Schweiz AG, TIC Holding Schweiz AG, and other portfolio companies. 

 

For press inquiries, please contact presse@winterberg.group 

Note for Editors: Please reference Dealert.AI and Winterberg Group AG for any provided quotes and information. 

For more information about Dealert.AI, visit https://dealert.ai

For more information about Winterberg Group AG, visit www.winterberg.group  

For more information about the portfolio of Winterberg Group AG visit www.healthcare-holding.ch and www.tic-holding.ch 

This press release is issued and distributed by Dealert.AI and Winterberg Group AG. 

Healthcare Holding Schweiz AG, a leading service provider and distributor of medical devices in Switzerland, is expanding its portfolio with the acquisition of Effectum CH-Rep AG. Healthcare Holding Schweiz is managed by Winterberg Advisory and KKA Partners. 

Baar, Switzerland – March 2025

Healthcare Holding Schweiz AG has successfully completed the acquisition of Effectum CH-Rep AG. This transaction marks a carve-out of all services provided as Swiss Authorized Representative (CH-REP) from Effectum Medical AG. Under the Medical Devices Ordinance (MedDO SR 812.213) effective since May 26, 2021, manufacturers of medical devices without a registered office in Switzerland must appoint a CH-REP to distribute their products within the country. Through this acquisition, Healthcare Holding Schweiz AG strengthens its position as a comprehensive partner for medical technology manufacturers worldwide. With its group of companies, it can now provide integrated services that encompass not only import and distribution but also full compliance with regulatory requirements. 

Fabio Fagagnini, CEO of Healthcare Holding Schweiz, expressed his enthusiasm for the acquisition: “With Effectum CH-Rep, we are expanding our service portfolio to include the role of Swiss Authorized Representative, thereby strengthening our growing group. This allows our sales representatives and managing directors to focus even more on innovative products and exceptional customer service, with the assurance that all regulatory requirements are being professionally met.” 

Kim Züger, Head of Quality Management & Regulatory Affairs and the newly appointed Director of Effectum CH-Rep, emphasized: “Regulatory compliance is our top priority. Through Effectum CH-Rep, we offer this service not only to suppliers of Healthcare Holding Schweiz but also to numerous other manufacturers—a clear testament to our professionalism and high-quality standards.” 

Michael Eggimann, Board Member of Effectum Medical AG and responsible for the sale of Effectum CH-Rep AG, added: “We have valued working with Fabio Fagagnini and his team for many years and are confident that Effectum CH-Rep is in excellent hands. This transition allows us to fully concentrate on the further development and distribution of our Legal Manufacturing offering as well as our innovative plug-and-play quality management system, while continuing to collaborate closely with Effectum CH-Rep for the benefit of our customers.” 

About Effectum CH-Rep AG 

Effectum CH-Rep AG, based in Olten, facilitates access for foreign manufacturers of medical devices to the Swiss market by acting as the Swiss Authorized Representative (CH-REP). As a CH-REP, Effectum CH-Rep AG takes on responsibilities such as ensuring compliance with Swiss registration requirements, collaborating with Swissmedic on preventive and corrective actions, providing a Person Responsible for Regulatory Compliance (PRRC), guaranteeing access to technical documentation, and reporting incidents and complaints.  

About Healthcare Holding Schweiz AG 

Healthcare Holding Schweiz AG is a Buy, Build & Technologize platform and a leading provider of medical technology products and services in Switzerland. The group is based in Baar and pursues an ambitious growth strategy through acquisitions, often in the context of succession arrangements, partnerships, and organic growth. Healthcare Holding Schweiz and its group companies are committed to the highest standards of innovation and customer satisfaction. The group consistently leverages technology to make business processes safer and more efficient. As a market leader, the company sets new standards for the industry and offers employees attractive development opportunities. All of the management team holds shares in Healthcare Holding Schweiz, thus forming a dynamic community of entrepreneurs. 

 

About KKA Partners

Founded in 2018, KKA Partners is a Berlin-based lower mid-market private equity firm that invests in leading companies in Germany, Austria and Switzerland – the so-called “Mittelstand”. The Founding Partners all have a deep-rooted family and professional heritage in the Mittelstand developed over 20 years in working closely with Mittelstand companies. KKA is at the forefront of the next wave of value creation through Technology Enabled Transformation of the Mittelstand.

 

About Winterberg Advisory GmbH and Winterberg Group AG 

Winterberg Group AG, based in Zug, operates as an independent family office for its founders. Winterberg mainly invests in SMEs in the German-speaking region, and selectively considers investments in startups and real estate. Winterberg Advisory GmbH is a general partner and fund manager regulated by the German BaFin. Winterberg Advisory has launched numerous private equity funds and is invested in Healthcare Holding Schweiz AG through its funds Winterberg Investment VIII and Winterberg Investment IX. The two Partners and Executive Directors, Fabian Kröher and Florian Brickenstein, manage Healthcare Holding Schweiz AG via its board of directors. 

 

For press inquiries, please contact presse@healthcare-holding.ch. 

Note for Editors: Please reference Healthcare Holding Schweiz AG for any provided quotes and information. 

For more information about Effectum CH-REP AG, visit www.effectum-chrep.com.

For more information about Healthcare Holding Schweiz AG, visit www.healthcare-holding.ch. 

For more information about the portfolio companies of Healthcare Holding, visit www.senectovia.ch, www.winthermedical.ch, www.mikrona.ch, www.orthowalker.ch, www.mcm-medsys.ch, www.naropa-reha.ch, www.mvb-medizintechnik.ch, www.dentalaxess.com.

For more information about KKA Partners visit www.kkapartners.com and about Winterberg www.winterberg.group.

This press release is issued and distributed by Winterberg Advisory GmbH on behalf of Healthcare Holding Schweiz AG. 

Mikrona Group AG, a leading Swiss manufacturer, service provider, and distributor of orthodontic products and equipment, has acquired Dental Axess AG, a specialist in digital dentistry operating in Switzerland. Mikrona Group is part of Healthcare Holding Schweiz AG, which is managed by Winterberg Advisory and KKA Partners. 

Schlieren, Switzerland – March 2025 

Mikrona Group AG has successfully completed the acquisition of Dental Axess AG, thereby strengthening its position in the field of digital dentistry. The product portfolio of Dental Axess AG includes state-of-the-art CAD/CAM products, intraoral scanners, 3D printers, X-ray devices, and software solutions. These technologies have significantly driven the digital transformation in dental practices and laboratories and continuously to gain market share. 

With the acquisition, the service and distribution business of Dental Axess in Switzerland will be separated from Dental Axess Holding AG. This strategic move allows the Dental Axess Group  to concentrate on its core mission of developing seamless digital workflows and proprietary software solutions for the dental industry while maintaining its distribution business outside of Switzerland. 

Fabio Fagagnini, CEO of Mikrona Group and Healthcare Holding Schweiz, emphasizes the importance of this step: “We are very proud to announce the successful acquisition of Dental Axess AG. Since 1959, Mikrona Group has been synonymous with the production and distribution of innovative products, and this strategic step strengthens our commitment to digitalization in dentistry. The advanced technologies and solutions of Dental Axess are groundbreaking in the industry. We are confident that this acquisition will allow us to further support doctors and patients in Switzerland and across Europe with the best and most innovative products.” 

Daniel Uebersax will continue to serve as Managing Director of Dental Axess AG and has acquired a stake in Healthcare Holding Schweiz as part of the transaction: “I am very excited about this new chapter in our rapid development. Healthcare Holding Schweiz and Mikrona Group provide the ideal environment for our team to continue growing. We can now fully focus on the service and distribution of our products. Personally, I am especially pleased to join a group of entrepreneurs as an entrepreneur myself and benefit from the mutual exchange of experience from various fields of medical technology.” 

Per Claesson, CEO and co-founder of Dental Axess, adds: “Mikrona Group was our preferred candidate for our distribution business in Switzerland. We are absolutely confident that this transaction will significantly enhance the success of Dental Axess. This agreement allows us to focus on the continued development and global distribution of our innovative digital workflow solutions. Moreover, we maintain our commitment to providing exceptional support for our customers worldwide. This acquisition marks an important step in strengthening our position in the market and ensuring the long-term success of both companies. We are very pleased to have Dental Axess AG as a strong distribution partner in Switzerland by our side.” 

 

About Dental Axess AG  

Dental Axess AG, based in Zurich, is a leading provider of digital solutions in dentistry. The company distributes both the workflow and planning software of Dental Axess Holding AG as well as a comprehensive product portfolio of CAD/CAM products, intraoral scanners, 3D printers, thermoforming machines, cutting and milling machines, and X-ray devices. A steadily growing number of dental technicians, dentists, and specialists in Switzerland rely on the expert advice and service of Dental Axess AG.  

 

About Mikrona Group AG 

Mikrona Group AG, based in Schlieren, Switzerland, has been a leading provider of innovative solutions for orthodontists and dentists since 1959. The group unites the brands Mikrona and Ortho Walker, representing Swiss quality, innovation, and reliability. Mikrona is known for its state-of-the-art treatment units, which are regarded as the most innovative and high-quality in orthodontics across Europe. Through the acquisition of Ortho Walker, the group also distributes high-quality orthodontic products from almost all proven brand manufacturers and is by far the market leader in Switzerland. In addition, it has been offering an extensive training and continuing education program for orthodontists for many years. 

 

About Healthcare Holding Schweiz AG 

Healthcare Holding Schweiz AG is a “Buy, Build & Technologize” platform and a leading provider of medical technology products and services in Switzerland. The company group is based in Baar and pursues an ambitious growth strategy through acquisitions, often in the context of succession arrangements, partnerships, and organic growth. Healthcare Holding Schweiz and its group companies are committed to the highest standards of innovation and customer satisfaction. The group consistently leverages technology to make business processes safer and more efficient. As a market leader, the company sets new standards for the industry and offers employees attractive development opportunities. The whole management team holds shares in Healthcare Holding Schweiz, thus forming a dynamic community of entrepreneurs. Since 2024, the group has been led by CEO Fabio Fagagnini. 

 

About KKA Partners

Founded in 2018, KKA Partners is a Berlin-based lower mid-market private equity firm that invests in leading companies in Germany, Austria and Switzerland – the so-called “Mittelstand”. The Founding Partners all have a deep-rooted family and professional heritage in the Mittelstand developed over 20 years in working closely with Mittelstand companies. KKA is at the forefront of the next wave of value creation through Technology Enabled Transformation of the Mittelstand.

 

About Winterberg Advisory GmbH and Winterberg Group AG 

Winterberg Group AG, based in Zug, operates as an independent family office for its founders. Winterberg mainly invests in SMEs in the German-speaking region, and selectively considers investments in startups and real estate. Winterberg Advisory GmbH is a general partner and fund manager regulated by the German BaFin. Winterberg Advisory has launched numerous private equity funds and is invested in Healthcare Holding Schweiz AG through its funds Winterberg Investment VIII and Winterberg Investment IX. The two Partners and Executive Directors, Fabian Kröher and Florian Brickenstein, manage Healthcare Holding Schweiz AG via its board of directors. 

 

For press inquiries, please contact presse@healthcare-holding.ch. 

Note for Editors: Please reference Healthcare Holding Schweiz AG for any provided quotes and information. 

For more information about Dental Axess AG, visit www.dentalaxess.com.

For more information about Healthcare Holding Schweiz AG, visit www.healthcare-holding.ch. 

For more information about the portfolio companies of Healthcare Holding, visit www.senectovia.ch, www.winthermedical.ch, www.mikrona.ch, www.orthowalker.ch, www.mcm-medsys.ch, www.naropa-reha.ch, www.mvb-medizintechnik.ch  

For more information about KKA Partners visit www.kkapartners.com and about Winterberg Advisory GmbH www.winterberg.group.

This press release is issued and distributed by Winterberg Advisory GmbH on behalf of Healthcare Holding Schweiz AG. 

Switzerland’s economy, long synonymous with resilience, is set to defy broader Euro area sluggishness in 2025. Bolstered by stable inflation, a robust services sector, and targeted monetary easing, the country remains a beacon for investors seeking predictable returns. This analysis explores Switzerland’s macroeconomic trajectory, focusing on growth drivers, sectoral dynamics, and strategic opportunities. 

Outperformance in Core Indicators

 

Switzerland’s GDP is forecast to grow by 1.5% in 2025, accelerating to 1.9% in 2026—outpacing the Euro area’s estimated 0.8% growth (OECD; Goldman Sachs). As illustrated in Graph 1, Switzerland has maintained the second-highest quarterly GDP growth rate among the United States, United Kingdom, France, and Germany since Q2 2020—a reflection of its diversified economic base. 

Inflation, projected at 1% in 2025 for Switzerland, remains well below the Euro area’s 2% target. In Graph 2, we can see that Switzerland’s Harmonised Index of Consumer Prices has remained significantly lower than that of the European Union since 2021, reinforcing Switzerland’s strong price stability credentials.  

The Swiss National Bank (SNB) has cut interest rates by 50 basis points to 0.5% in December 2024, and further cuts can be expected in 2025 (OECD). This move is aimed at not only sustaining investment, but also private consumption, which accounts for over 50% of GDP. With real disposable incomes rising by 1% year-on-year in 2025 (OECD), household spending is poised to underpin growth even as external demand fluctuates. 

Switzerland’s 2025 trade outlook reflects a delicate balance between external headwinds and domestic strengths. The strong Swiss franc and subdued demand from Germany—where growth is forecast at just 0.3% in 2025 (Goldman Sachs)—pose risks to export volumes. However, Switzerland’s economic resilience stems from its dominance in high-value sectors. Pharmaceuticals, accounting for over 40% of goods exports (OECD), remain a cornerstone, driven by global giants like Roche and Novartis. The machinery and electronics sector, the second-largest export category, is adapting to weaker German industrial demand by pivoting to automation and robotics—a strategic shift aligned with Switzerland’s reputation for precision engineering (OECD). This dual focus on established strengths and innovation ensures stability even amid global volatility. 

Sectoral Dynamics: Healthcare, TIC, and Industrials 

Switzerland’s healthcare sector remains a key growth driver, fuelled by an ageing population and advancements in medical technology. Demand for precision diagnostics and innovative equipment is rising, yet recruitment challenges persist: 28% of healthcare roles requiring higher education faced staffing difficulties in 2024 (Swiss Federal Statistical Office). Addressing this gap through reskilling programmes and workforce retention strategies remains critical, as emphasised by the OECD. For instance, initiatives to integrate migrant women into the healthcare workforce—where participation lags at 65% compared to 78% for Swiss-born women—could alleviate shortages (OECD). 

Parallel to healthcare, the testing, inspection, and certification (TIC) sector is gaining traction. Rigorous regulatory requirements—spanning medical devices, industrial machinery, and beyond—are amplifying demand for specialised compliance services. This aligns with Switzerland’s global reputation for precision, positioning TIC firms to capitalise on cross-industry opportunities. Companies such as Société Générale de Surveillance (SGS) dominate this niche, leveraging Switzerland’s regulatory frameworks to secure contracts in emerging markets. The OECD estimates TIC services could contribute an additional 0.3% to annual GDP growth by 2026 if digital transformation accelerates. 

While the broader industrial sector contends with energy cost pressures and competitive headwinds, niche areas such as precision engineering continue to thrive. These segments, supported by Switzerland’s expertise in high-value manufacturing, are nonetheless seeing weaker performance in traditional industries (OECD). For example, the machinery sector—which contributes 12% to total exports—is actively diversifying into automation and robotics, mitigating risks from slowing German industrial demand. 

Challenges: Labour Mismatches and Geopolitical Risks 

Despite a low unemployment rate (4.0% in 2025), structural labour shortages in healthcare, engineering, and IT persist. The OECD advocates for policies to boost workforce participation, including reskilling programmes and incentives for delayed retirement. Currently, only 35% of Swiss workers aged 60–64 remain employed, compared to 45% in Sweden (OECD), highlighting untapped potential. 

Geopolitically, energy price volatility—linked to geopolitical tensions—poses risks, though Switzerland’s diversified energy mix mitigates exposure (Swiss Federal Statistical Office). Hydropower and nuclear energy supply over 60% of domestic electricity, reducing reliance on imported fossil fuels. However, a prolonged downturn in Germany or China—Switzerland’s second- and third-largest export markets—could dampen demand. Goldman Sachs warns that a 1% contraction in German GDP could shave 0.2% off Swiss growth, underscoring interconnected risks. 

Conclusion: Switzerland’s Enduring Investment Appeal 

Switzerland’s 2025 outlook cements its status as an investment haven. With inflation anchored, growth outperforming peers, and a services-driven economy, the country balances stability with strategic innovation. Niche sectors such as healthcare and TIC exemplify its ability to leverage specialised expertise into macroeconomic resilience. 

Fabian Kroeher, Managing Partner at Winterberg Group, provides insight into Switzerland’s broader macroeconomic positioning:

“Switzerland continues to set itself apart from the broader European economy by maintaining macroeconomic stability amid global uncertainty. A strong currency, low inflation, and sectoral resilience—particularly in healthcare, precision engineering, and financial services—create an attractive environment for long-term investment. The Swiss economic model, underpinned by fiscal discipline and innovation, ensures that it remains a safe haven for capital even as other regions struggle with structural challenges.” 

The healthcare sector’s alignment with demographic trends—coupled with TIC’s role in upholding rapidly evolving standards—positions Switzerland to thrive even as global trade faces turbulence. Meanwhile, the industrial sector’s focus on high-value niches ensures continued relevance in competitive markets. 

As global uncertainty persists—from trade tensions to geopolitical strife—Switzerland’s blend of prudence and adaptability offers investors a rare combination of safety and growth potential. For those navigating turbulent markets, the Alpine nation remains a strategic stronghold.